Xbp1, a protein involved in the unfolded protein response, is a rare example of a mammalian protein that contains a well-defined translational arrest peptide (AP). In order to define the critical residues in the Xbp1u AP, and to search for variants with stronger arrest potency than the wildtype Xbp1u AP, we have carried out a full mutagenesis scan where each residue in the AP was replaced by the other 19 natural amino acids. We find that 10 of the 21 mutagenized positions are optimal already in the wildtype Xbp1 AP, while certain mutations in the remaining residues lead to a strong increase in the arrest potency. Xbp1 has thus evolved to induce an intermediate level of translational arrest, and versions with much stronger arrest efficiency exist. We further show Xbp1-induced translational arrest is reduced in response to increased tension in the nascent chain, making it possible to carry out studies in mammalian systems of cotranslational processes such as membrane protein assembly and protein folding by using suitable Xbp1 AP variants as "force sensors", as has been done previously in E. coli using bacterial APs.
Introduction
During protein synthesis, the nascent polypeptide chain moves through the approximately 100 Å long exit tunnel in the large ribosomal subunit (1) . While most peptide sequences move through the tunnel unimpeded, some nascent chain segments are able to interact with the ribosome exit tunnel in ways that stall translation for various lengths of time (2, 3) . Such translational arrest peptides (APs) interact with distinct ribosomal RNA and protein components within the ribosome exit tunnel (4) , inducing conformational changes in the ribosome active site that can block the peptidyl-transfer reaction (5) (6) (7) (8) . In bacteria, such translational arrest peptides (APs) are often used to regulate the translation of downstream open reading frames in polycistronic mRNAs (3) . The best studied mammalian AP, found in the Xbp1 protein, is critical for proper regulation of the unfolded protein response (9) .
The E. coli SecM AP is exquisitely sensitive to pulling forces that act on the nascent chain (10, 11) . In bacteria, APs can therefore be used use as transplantable in vivo force sensors in the study of cotranslational processes where an outside agent exerts a pulling force on the nascent chain, such as cotranslational translocation of charged residues in the nascent chain across the inner membrane (12) , insertion of transmembrane helices into the inner membrane (10) , and folding of a cytoplasmic protein in the ribosome exit tunnel (11, (13) (14) (15) .
So far, the only mammalian AP that has been tested as a force sensor is the one found in Xbp1 (10) . However, compared to bacterial APs, the Xbp1 AP is rather long and has weaker arrest potency, and hence is not very useful when analyzing processes that generate large pulling forces on the nascent chain. We therefore decided to submit the human Xbp1 AP to saturation mutagenesis in the hope that versions with stronger arrest potency would be found. We now report mutant Xbp1 APs with much higher arrest potency than the original one that can be significantly shortened without serious loss of arrest potency. These Xbp1-derived APs allow the AP-based force measurement assay to be used to analyze cotranslational processes in mammalian in vitro translation systems, as exemplified here by analyses of membrane protein insertion into rough microsomes and cotranslational folding of a small zinc-finger protein domain.
Our data show which residue is optimal for high arrest potency in each position in the Xbp1 AP, and therefore presumably interacts most strongly with the ribosome tunnel.
Results

Saturation mutagenesis of the Xbp1 arrest peptide
We previously screened for strong E. coli APs by expressing a protein construct where the cotranslational translocation of a string of negatively charged residues across the inner membrane generates a sufficiently strong pulling force on the nascent chain that the AP induces only weak translational stalling and systematically looking for mutations in the AP that would increase the degree of stalling (16) . Here, we used a similar approach but using the insertion of a hydrophobic transmembrane segment into ER-derived rough microsomes (RMs) to generate the pulling force. The starting construct is composed of an Nterminal part from E. coli leader peptidase (Lep) with two transmembrane segments (TM1, TM2), followed by a 155-residue loop, a third hydrophobic segment (H segment) of composition [6L,19A] that generates a pulling force when it inserts into the ER membrane (10), a linker, the 21-residue long human Xbp1 AP (with a previously identified S-7→A mutation that increases the arrest potency compared to the wildtype Xbp1 AP (9)), and a 24-residue long C- In addition, we repeated the screen using a stronger version of the AP with the additional mutation P-8→V, that, according to the first screen, increases the arrest efficiency of the AP (fFL = 0.46). In this second screen, we focused mainly on positions for which most mutations in the first screen gave fFL ≈ 1, in order to 6 detect any patterns among the mutations that weakened the arrest efficiency of the AP. As can be seen in Fig. 3b , all positions except position -7 showed a graded response to different mutations; for the latter, all residues except A gave fFL =1.0.
Interestingly, mutations Q-9→[L, C] led to a reduction in fFL, despite the fact that the same mutations led to an increase in fFL in the first screen (Fig. 3a) .
Apparently, the identity of the neighboring residue in position -8 (Pro or Val) affects the way residue -9 interacts with the ribosome tunnel.
Some general patterns are discernible from the data in Fig. 3 . Many residues in the wildtype Xbp1 AP are optimal or close to optimal for efficient translation arrest: Y-21, P-18, L-16, W-13 to H-10, W-6 to P-4, and M-2. In contrast, some residues in the wildtype AP are clearly sub-optimal in terms of translation arrest: Q-20, P-19, F-17, C-15, Q-9, and P-8. Residue A-7 -the only mutation that was found to decrease fFL in the original Ala-scan (9) -stands out in that even the most conservative substitutions lead to a large increase in fFL.
There is a reasonable correspondence between the results from the mutational screen and the consensus motif around translational arrest sites found in a large ribosome-profiling study of mouse embryonic stem cells (17) , where the most common residues are E and D in position -1, P and G in position -2, and P in position -3. In the Xbp1 AP, D and L are the most efficiently stalling residues in position -1, G, F, and P the most efficient in position -2, and P the fifth most efficient in position -3 (Fig. 3a) .
We conclude that the Xbp1 AP has not evolved to maximal arrest potency, and that versions with considerably stronger arrest efficiency can be obtained.
Analysis of arrest-enhanced variants of the Xbp1 arrest peptide
As a more stringent test of the identified Xbp1 mutations, we re-measured the force profile in Fig. 2 using the strong Xbp1(S-7→A, P-8→C) AP (blue curve in Fig.   2) . fFL values are reduced throughout, while the shape of the profile persist.
Interestingly, the early peak at L ≈ 30 residues seen for the same H-segment constructs expressed in E. coli with the SecM AP (10) (grey curve) is not clearly seen in the mammalian force profiles, suggesting that the H segment interacts differently with the Sec61 and SecYEG translocons at early stages of membrane insertion. Because the mutation in residue P-8 introduces a Cys residue in the nascent chain, we considered that the enhanced arrest potency may due to the formation of a disulfide bond with a ribosomal protein, or within the nascent chain itself. However, no crosslinked product is apparent when the gel is run In addition, we measured a force profile where the force on the nascent chain is generated by the cotranslational folding of a small protein domain, the 29-residue zinc-finger domain ADR1a, again using the stronger Xbp1(S-7→A, P-8→C)
AP (but in this case lacking residues Y-21 and Q-20). Cotranslational folding of
ADR1a has previously been analyzed in an E. coli-derived PURE in vitro translation system, where ADR1a was found to fold rather deep inside the ribosome exit tunnel, at tether lengths L ≈ 22-26 residues (14) . We expressed two series of ADR1a-Xbp1 constructs in the rabbit reticulocyte in vitro translation system (no RMs included) supplemented with 1 mM ZnCl2, using either wildtype ADR1a or a mutant where the four Zn 2+ -binding residues were simultaneously mutated to Ala. As shown in Fig. 4 , fFL values are significantly higher for wildtype ADR1a than for the mutant for L = 20-22 residues, i.e., at slightly shorter tether lengths than seen in the E. coli system. The dip in the curves for the wildtype and mutant at L = 20 residues (Fig. 4, inset) is presumably caused by small variations in fFL induced by residues located further than 19 residues away from the P-site, as only the last 19 residues of the Xbp1 AP are kept constant in the ADR1a series of constructs. It thus appears that ADR1a can fold even deeper inside the ribosome exit tunnel in mammalian ribosomes compared to E. coli ribosomes.
Discussion
While a growing number of APs have been identified in bacteria (3), the only reasonably well-characterized mammalian AP is the one found in the Xbp1 protein (9) . In order to determine which residues in the Xbp1 AP that are critical for its translational arrest function, and to identify mutant versions that may be used as force sensors in studies of cotranslational processes such as protein folding and membrane protein assembly, we have carried out a systematic mutational screen of the Xbp1 AP. While 10 of the 21 mutagenized positions are optimal already in the wildtype Xbp1 AP in the sense that all mutations in these positions lead to weaker translational arrest, certain mutations in residues Q-20, P-19, F-17, C-15, Q-9, and P-8 lead to a strong increase in the arrest potency (Fig. 3) .
As shown in Fig. 2 
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Enzymes and chemicals. Unless stated otherwise, all chemicals were from SigmaAldrich (St Louis, MO, USA). Oligonucleotides were purchased from MWG Biotech AG (Ebersberg, Germany). Pfu Turbo DNA polymerase was purchased from Agilent Technologies. All other enzymes were from Fermentas. The plasmid pGEM-1 and the TNT SP6 Transcription/Translation System were from Promega. 
